Business Wire

HISENSE

1.6.2021 12:00:08 CEST | Business Wire | Press release

Share
Building Sustainable Future: Hisense and Employees

Living under the new-normal, ESG has become one of the world's most trending topics. A positive impact on society and providing sustainable development opportunities for employees have gradually become the new criteria for companies to represent their growth. By putting talent first, Hisense strives to build a global team that includes people from different cultures and unique experiences, and to provide an equal and healthy working environment to drive its success. Together with over 90,000 employees around the world, Hisense is creating a sustainable future and exerting positive social influence constantly.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005474/en/

Focusing on local talent cultivation and cultural inclusion

Hisense supports local communities to relieve their unemployment pressure and to reduce the indirectly related crime rate. Through its investment in industrial parks worldwide, Hisense creates more than 3,000 job positions in South Africa and over 2,000 in Mexico with an expectation to expand to over 7,000 in the future, which successfully helps the local region expand its economy and boost sustainable development.

Hisense provides equal employment opportunities regardless of race and gender with professional and systematic training when recruiting local employees. For example, Nicalette, a single mother, who joined Hisense South Africa in 2002, was promoted to After-sales Manager through her excellent work performance and rapidly growing ability. Hisense’s talent employment and cultivation system has increased her passion for work and also made her life improved, according to Nicalette.

Caring for employees' career development

To empower employees, Hisense has created the necessary conditions and space for them to maximize their potential and value. Hisense implements a flexible promotion mechanism, allowing employees to choose between career paths of “management” and “R&D” for further development, which ensures a smooth promotion channel for everyone.

Hisense College, the corporate university, aims to help employees achieve better career development. A comprehensive training structure and multiple internal training platforms (including offline lecture, website, APP, etc.) are in place to help employees learn and improve anytime, anywhere.

"What makes working here different from other companies is that Hisense always motivates its employees to accomplish career goals and gives them great supports, allowing them to grow with the company." said Robin Silberbauer, who joined Hisense South Africa in 2015.

Caring for employees' health and wellbeing

During the pandemic, Hisense spares no efforts to assure employees' and their families' health through distributing epidemic prevention materials and supporting working at home.

Hisense also joins hands with professional EAP (“Employee Assistance Program”) organizations to provide mental health care for employees and their families, so that each employee can easily obtain professional psychological counselling services, which efficiently help them improve mental health and take up challenges of work and life.

Hisense will focus on talent development in the long term and actively create an inclusive workplace environment to advance the sustainable development of local communities with its global workforce.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye